Frequent coauthors
- WALLACE Owen Brendan 196
- FRANK SCOTT ALAN 196
- HUMMEL CONRAD WILSON 168
- JONES SCOTT ALAN 168
- SHEPHERD TIMOTHY ALAN 154
- DALLY ROBERT DEAN 140
- Jones Charles David 112
- Lewis George Sal 112
- Fahey Kennan Joseph 98
- Bryant Henry Uhlman 98
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.